Search Results
Found 2 results
510(k) Data Aggregation
(78 days)
The CryOmega Flexx is intended for the surgical destruction of tissue by applying cryogenic gases at extreme low temperatures.
The List below shows examples of the types of lesions that may be treated:
- Molluscum Contagiosum
- · Skin Tags
- · Actinic Keratosis
- Lentigo
- · Verruca Plana
- · Verruca Vulgaris
- Verruca Plantaris
- · Genital Lesions
- · Seborrheic Keratosis
The CryOmega Flexx device is designed to dispense a continuous stream of liquid nitrous oxide when actuated. The device uses a 16g or 25g cartridge of nitrous oxide that is sprayed once the gas cartridge has been screwed onto the applicator. Licensed Practitioners can then dispense the gas for use in procedures requiring the destruction of tissue using the extreme cold of nitrous oxide, N2O (-89ºC).
Here's an analysis of the provided text regarding the acceptance criteria and supporting study for the CryOmega Flexx device:
The document is a 510(k) premarket notification summary for the CryOmega Flexx, a cryosurgical unit. It focuses on demonstrating substantial equivalence to a predicate device (CryOmega-K102006) rather than defining and proving new acceptance criteria for novel performance claims. Therefore, the "acceptance criteria" here are essentially the performance characteristics of the predicate device, which the new device must meet or be substantially equivalent to.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria (from Predicate Device Performance) | Reported CryOmega Flexx Performance |
|---|---|
| Cryogen Temperature at Treatment Site: -89°C | "replicate measurements of gas sprayed onto a thermocouple from each device were all less than -90°C" (This indicates it meets or exceeds the predicate's reported temperature.) |
| Amount of Gas Dispensed: (Implied by predicate) | "replicate sprays of each device were performed, weighing the devices before and after a 5 second spray. The amount dispensed for the CryOmega Flexx and CryOmega were calculated and found to be <1.0% different. The difference in amount dispensed was therefore negligible." (This demonstrates equivalency in gas dispensed.) |
| Cellular Destruction Efficacy: (Implied by predicate's mechanism of action) | "the spray of liquid nitrous oxide was previously shown to destroy red blood cells immobilized in agar. A spray of the device was able to reach a depth of approximate 1.0 mm after a 5 second spray." (This relies on prior validation of the predicate's mechanism, and confirms the new device achieves a similar physical effect (spray depth) which is linked to efficacy.) It's important to note this isn't a direct measure of efficacy for the listed lesions, but rather a physical proxy. |
| Safety: Complies with ASTM F882-84 (96) | "Complies with ASTM: F882-84 (96) for Cryosurgical Medical Instruments" (Declared compliance with the same standard as the predicate.) |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: The document does not specify a precise sample size for the "replicate sprays" or "replicate measurements." It uses the term "replicate," implying multiple measurements were taken, but the exact number is not stated.
- Data Provenance: The study was a bench testing study conducted by the manufacturer, CryoConcepts LP. The data is prospective (generated specifically for this submission) and conducted in a controlled lab environment. There is no mention of country of origin for the data itself, but the manufacturer is based in Bethlehem, Pennsylvania, USA.
The study is essentially comparing the new device (CryOmega Flexx) directly against the predicate device (CryOmega-K102006) in terms of physical performance rather than against a clinical dataset of patients.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts
This type of information is not applicable to this study. The "ground truth" for this bench test study is objective physical measurements (temperature, mass, spray depth) taken by technical instruments, not expert human interpretation.
4. Adjudication Method for the Test Set
This is not applicable to this study as it involves objective physical measurements, not subjective human assessments requiring adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
This is not applicable. This document describes a bench testing study for a cryosurgical device, not an AI-powered diagnostic system or a study involving human readers.
6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done
This is not applicable. This device is a cryosurgical tool, not an algorithm. Performance is assessed through physical bench tests.
7. The Type of Ground Truth Used
The ground truth used in this study is based on objective physical measurements obtained from bench testing instruments (thermocouple for temperature, scale for mass, and a visual assessment of spray depth in agar for the cellular destruction proxy).
8. The Sample Size for the Training Set
This is not applicable. This device does not use machine learning or AI, and therefore does not have a "training set."
9. How the Ground Truth for the Training Set Was Established
This is not applicable for the same reason as above; there is no training set.
Ask a specific question about this device
(82 days)
The CryOmega is a disposable device intended for the surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures. The list below shows examples of the type of lesions that can be treated.
-Genital Lesions -Molluscum Contagiosum -Seborrheic Keratoses -Skin Tags -Verruca Plantaris -Verruca Vulgaris -Verruca Plana -Actinic Keratosis -Lentigo
The CryOmega device is designed to dispense a continuous stream of liquid nitrous oxide when actuated. The device contains a 16g cartridge of nitrous oxide that is dispensed once the device is activated. Physicians or medical professionals can then dispense the gas for use in procedures requiring the destruction of tissue using the extreme cold of nitrous oxide (-89°C). Unlike the predicate device, the CryOmega is designed to be self contained and disposable after all of the liquefied gas has been dispensed.
The provided text is a 510(k) Premarket Notification Summary for the CryOmega device. It focuses on demonstrating substantial equivalence to a predicate device (Cryoprobe-C) rather than presenting a standalone study with detailed acceptance criteria and performance metrics typically found for AI/software-as-a-medical-device (SaMD) clearances.
Therefore, much of the requested information regarding AI device testing (such as sample sizes for test/training sets, expert ground truth, adjudication methods, MRMC studies, or standalone performance for an algorithm) is not applicable to this document. The CryOmega is a physical cryosurgical unit, not an AI/software device.
However, I can extract information related to the device's characteristics and the basis for its substantial equivalence.
Here's a breakdown of the requested information based only on the provided text:
1. A table of acceptance criteria and the reported device performance
Since this is a 510(k) for a physical device, the "acceptance criteria" are not framed as statistical performance metrics for an algorithm but rather as characteristics demonstrating substantial equivalence to a predicate device. The "reported device performance" is essentially a comparison of its characteristics to the predicate.
| Characteristic / "Acceptance Criteria" | Predicate Device (Cryoprobe-C K024009) | CryOmega (Reported Device Performance) |
|---|---|---|
| Intended Use | To destroy tissue during surgical procedures by applying extreme cold. | Disposable device intended for surgical destruction of target tissue by applying cryogenic gases at extreme low temperatures. Examples of treatable lesions listed: Genital Lesions, Molluscum Contagiosum, Seborrheic Keratoses, Skin Tags, Verruca Plantaris, Verruca Vulgaris, Verruca Plana, Actinic Keratosis, Lentigo. |
| Cryogen Characteristics | Nitrous Oxide, N2O at 50 bar pressure. 8g or 16g cartridges. | Nitrous Oxide, N2O at 50 bar pressure. 16g cartridge. |
| Materials | Housing: Aluminum; Micro-Applicator: unknown; Lock Cap: Plastic; Filter: Unknown; O-rings: Unknown; Cartridge: Metal. | Housing: Plastic; Filter: Plastic; O-rings: Butadiene-rubber; Cartridge: Metal. |
| Mode of Use | Apply Spray Topically. | Apply Spray Topically. |
| Mechanism of action | N2O gas is delivered to the treatment site at -89°C to effect cellular destruction. | N2O gas is delivered to the treatment site at -89°C to effect cellular destruction. |
| Storage Conditions | <50°C | <50°C |
| Safety (ASTM Standard) | Complies with ASTM: F882-84 (96) for Cryosurgical Medical Instruments. | Complies with ASTM: F882-84 (96) for Cryosurgical Medical Instruments. |
| Gas Cartridge Safety | Cartridge can expel unused gas under pressure during cartridge replacement. | Unit is discarded after liquefied gas is emptied (implying increased safety due to inaccessibility of high-pressure cartridge). |
| Treatment Procedure | Suggests Freezing of target tissue by spray. | Same. |
| Operation | Spray begins when gas cartridge is engaged. Continuous spray unless capped. | Gas dispensed using actuator lever. Spray controlled by on/off actuator. |
| Disposal | Main Unit is reusable with replaceable gas cartridges. | Whole Unit is disposable after liquefied gas is emptied from the cartridge. |
| Defined Operators | Physician or Licensed Practitioner. | Same. |
| Service/Repair | Return to Manufacturer. | Disposable once liquefied gas is emptied. No Servicing. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
This information is not applicable as the document describes a physical medical device (cryosurgical unit), not a software or AI device requiring a test set of data. The "testing" mentioned refers to engineering and safety verifications, not clinical performance studies with patient data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
This information is not applicable. Ground truth for image interpretation or diagnosis is not relevant for this type of device submission.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
This information is not applicable.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
This information is not applicable. This is not an AI-assisted device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
This information is not applicable.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
This information is not applicable. The "ground truth" relevant to this submission is the established performance and characteristics of the legally marketed predicate device (Cryoprobe-C) to which the CryOmega is being compared for substantial equivalence.
8. The sample size for the training set
This information is not applicable.
9. How the ground truth for the training set was established
This information is not applicable.
Ask a specific question about this device
Page 1 of 1